Pfizer Inc (PFE) 34.78 $PFE
Don't Sell Qualcomm; Stick With Companies That Have Growth
at The Street - Thu Jul 23, 2:04PM CDT
The CNBC 'Fast Money' traders debate whether now is a good time to sell Qualcomm, and discuss a raft of other stocks.
AMZN: 482.18 (-6.09), NKE: 114.00 (-0.09), FB: 95.44 (-1.60), PFE: 34.78 (-0.10), C: 59.87 (-0.47), LLY: 86.76 (+0.38), BMY: 68.24 (-1.13), INTC: 28.59 (-0.01), HPQ: 31.23 (+0.46), FINL: 27.44 (-0.43), NFLX: 110.10 (-1.40), UA: 95.93 (+6.56), JPM: 69.64 (-0.44), IBM: 161.73 (+1.38), QCOM: 61.78 (-2.41), FFIV: 127.68 (+9.18), CRUS: 35.72 (+5.01), GOOGL: 674.73 (-20.37), FL: 69.90 (-0.36), AAPL: 125.16 (-0.06), FTNT: 46.83 (+4.53), CSCO: 28.01 (+0.48)
Bristol-Myers Beats on Q2 Earnings, Raises 2015 Guidance - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 23, 12:32PM CDT
Bristol-Myers Squibb Company's (BMY) second-quarter 2015 earnings (excluding special items) of 53 cents per share beat the Zacks Consensus Estimate of 35 cents.
PFE: 34.78 (-0.10), SNSS: 3.47 (-0.05), AMAG: 71.31 (-1.23), BMY: 68.24 (-1.13)
How to Trade 5 Big Stocks for Big Gains -- Must-See Charts
at The Street - Thu Jul 23, 11:42AM CDT
Here's a technical look at how to trade some of the biggest stocks on Wall Street.
HD: 114.59 (-0.31), V: 71.75 (-0.22), GS: 211.05 (-2.20), CNI: 60.22 (-0.78), PFE: 34.78 (-0.10)
Zacks Industry Outlook Highlights: AbbVie, Allergan, Pfizer, Juno and Johnson & Johnson - Press Releases
Zacks Equity Research - Zacks Investment Research - Wed Jul 22, 8:30AM CDT
Zacks Industry Outlook Highlights: AbbVie, Allergan, Pfizer, Juno and Johnson & Johnson
AGN: 314.95 (-0.40), JNJ: 100.20 (+0.02), PFE: 34.78 (-0.10), JUNO: 51.65 (-0.12), ABBV: 70.52 (-0.04)
Pfizer Announces Expansion of Lease Agreement with Massachusetts Institute of Technology Subsidiary for Kendall Square Research Facility
Business Wire - Wed Jul 22, 7:30AM CDT
Pfizer announced today the expansion of its lease agreement with a subsidiary of Massachusetts Institute of Technology, creating a unified Pfizer campus in Kendall Square (KSQ). With this expansion, Pfizer has leased the full 500,000 square feet at 610 Main Street in Kendall Square. This space will continue to house the R&D activities that relocated to 610 Main Street in 2014, and will enable the consolidation of Pfizer's three other leased spaces in Cambridge into the one campus.
PFE: 34.78 (-0.10)
2015’s Top 6 Big Pharma Headlines Thus Far
George Budwell, The Motley Fool - Motley Fool - Wed Jul 22, 7:16AM CDT
The pharmaceutical industry has certainly gotten off to another wild start in 2015. Despite the year being only half over at this point, we've already seen dozens of high profile mergers, several closely-watched experimental drugs report pivotal...
JNJ: 100.20 (+0.02), PFE: 34.78 (-0.10), AMGN: 164.10 (-0.15), ABBV: 70.52 (-0.04), BMY: 68.24 (-1.13)
Bristol-Myers Shares Come With an Unhealthy Dose of Optimism
at The Street - Wed Jul 22, 5:15AM CDT
Bristol-Myers Squibb now trades at an unusually high price-to-earnings ratio of 51. If you own it, take some profits before Thursday's earnings report. If you don't, look elsewhere.
JNJ: 100.20 (+0.02), PFE: 34.78 (-0.10), BMY: 68.24 (-1.13)
Pfizer is expanding its vaccine portfolio, developing others
By The Associated Press - AP - Tue Jul 21, 5:08PM CDT
Pfizer has expanded its research on vaccines to eventually safeguard people from cradle to grave, from shots for pregnant women to protect their babies from the moment of birth to vaccines for senior citizens with waning immune systems, company officials said Tuesday during a media briefing.
BAX: 37.97 (+0.26), PFE: 34.78 (-0.10)
Business Highlights
By The Associated Press - AP - Tue Jul 21, 5:00PM CDT
___
JPM: 69.64 (-0.44), PFE: 34.78 (-0.10), C: 59.87 (-0.47), AMGN: 164.10 (-0.15), BAC: 18.18 (-0.27)
Pharma Stock Outlook - July 2015 - Zacks Analyst Interviews
Arpita Dutt - Zacks Investment Research - Tue Jul 21, 1:52PM CDT
Pharma Stock Outlook - July 2015 - Zacks Analyst Interviews
AGN: 314.95 (-0.40), JNJ: 100.20 (+0.02), ACHN: 8.97 (-0.12), PFE: 34.78 (-0.10), ABBV: 70.52 (-0.04), JUNO: 51.65 (-0.12), LLY: 86.76 (+0.38), SNY: 53.37 (+0.28)
Pharma Stock Outlook - July 2015 - Industry Outlook
Arpita Dutt - Zacks Investment Research - Tue Jul 21, 1:52PM CDT
Pharma Stock Outlook - July 2015 - Industry Outlook
AGN: 314.95 (-0.40), JNJ: 100.20 (+0.02), ACHN: 8.97 (-0.12), PFE: 34.78 (-0.10), ABBV: 70.52 (-0.04), JUNO: 51.65 (-0.12), LLY: 86.76 (+0.38), SNY: 53.37 (+0.28)
Europe approves Amgen's first-in-class cholesterol drug
By MATTHEW PERRONE - AP - Tue Jul 21, 1:32PM CDT
WASHINGTON (AP) — Amgen on Tuesday received European approval for its first-of-a-kind cholesterol drug that lowers levels of the artery-clogging substance more than older drugs that have been prescribed for decades.
PFE: 34.78 (-0.10), AMGN: 164.10 (-0.15)
Global Fibrosis Therapeutics Pipeline Report 2015 - 32 Companies & 51 Drug Profiles
M2 - Tue Jul 21, 10:39AM CDT
Research and Markets (http://www.researchandmarkets.com/research/rjw3lt/fibrosis) has announced the addition of the "Fibrosis - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Fibrosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Fibrosis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Acceleron Pharma, Inc. - AiCuris GmbH & Co. KG - AnaMar AB - Arena Pharmaceuticals, Inc. - Bristol-Myers Squibb Company - Digna Biotech, S.L. - F. Hoffmann-La Roche Ltd. - FibroGen, Inc. - Five Prime Therapeutics, Inc. - Galectin Therapeutics, Inc. - GenKyoTex S.A. - GlycoMimetics, Inc. - HanAll Biopharma Co., Ltd. - Intercept Pharmaceuticals, Inc. - Isarna Therapeutics GmbH - KineMed, Inc. - Lycera Corp. - MandalMed, Inc. - miRagen Therapeutics, Inc. - Neumedicines Inc. - Pfizer Inc. - Promedior, Inc. - ProMetic Life Sciences Inc. - RuiYi Inc. - Scholar Rock, Inc. - Siena Biotech S.p.A. - SK Chemicals Co., Ltd. - Taisho Pharmaceutical Co., Ltd. - TRACON Pharmaceuticals, Inc. - UCB S.A. - Vericel Corporation - VivaCell Biotechnology Espana S.L. For more information visit http://www.researchandmarkets.com/research/rjw3lt/fibrosis
VCEL: 3.47 (-0.03), KNMD: (), PFE: 34.78 (-0.10), GALT: 2.83 (+0.10), GLYC: 7.52 (+0.05), BMY: 68.24 (-1.13), ICPT: 280.00 (+10.69), FGEN: 24.71 (+0.25), TCON: 13.02 (-0.14), ARNA: 4.15 (-0.10), XLRN: 31.50 (-0.68), FPRX: 24.47 (-0.58)
Sickle Cell Disease Pipeline Review, H1 2015 - 27 Companies & 48 Drug Profiles
M2 - Tue Jul 21, 10:39AM CDT
Research and Markets (http://www.researchandmarkets.com/research/rrc4sf/sickle_cell) has announced the addition of the "Sickle Cell Disease - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Sickle Cell Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Sickle Cell Disease and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Acceleron Pharma, Inc. - Acetylon Pharmaceuticals, Inc. - Addex Therapeutics Ltd - Advinus Therapeutics Ltd. - Alnylam Pharmaceuticals, Inc. - Bluebird bio, Inc. - Bristol-Myers Squibb Company - Daiichi Sankyo Company, Limited - Dilaforette AB - Emmaus Medical, Inc. - Errant Gene Therapeutics, LLC - Erytech Pharma SA - Gamida Cell Ltd. - Gilead Sciences, Inc. - Global Blood Therapeutics, Inc. - Isis Pharmaceuticals, Inc. - Johnson & Johnson - Morphogenesis, Inc. - NKT Therapeutics, Inc. - Novartis AG - Pfizer Inc. - PharmaEssentia Corporation - Prolong Pharmaceuticals - ReveraGen BioPharma, Inc. - Sangamo BioSciences, Inc. - Sanofi - SynZyme Technologies, LLC For more information visit http://www.researchandmarkets.com/research/rr...ickle_cell
JNJ: 100.20 (+0.02), ISIS: 55.08 (-0.30), GILD: 117.66 (+0.22), PFE: 34.78 (-0.10), SGMO: 8.83 (-0.77), BMY: 68.24 (-1.13), NVS: 103.05 (+1.75), XLRN: 31.50 (-0.68)
Clostridium Difficile Infections (Clostridium Difficile Associated Disease) Therapeutics Pipeline Report 2015 - 37 Companies & 57 Drug Profiles
M2 - Tue Jul 21, 10:33AM CDT
Research and Markets (http://www.researchandmarkets.com/research/vgmkjs/clostridium) has announced the addition of the "Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Clostridium Difficile Infections (Clostridium Difficile Associated Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Clostridium Difficile Infections (Clostridium Difficile Associated Disease) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Absynth Biologics Limited - Actelion Ltd - ActogeniX NV - Adenium Biotech ApS - AIMM Therapeutics B.V. - Akthelia pharmaceuticals ehf - AmpliPhi Biosciences Corporation - Assembly Biosciences, Inc. - AvidBiotics Corp. - C3 Jian, Inc - Daiichi Sankyo Company, Limited - Evec, Inc. - GangaGen Inc. - ImmunoBiology Ltd. - Immuron Limited - Inovio Pharmaceuticals, Inc. - MedImmune, LLC - Merck & Co., Inc. - MGB Biopharma Limited - Microbiotix, Inc. - Micropharm Ltd - Nanotherapeutics, Inc. - Novabiotics Ltd - Oragenics, Inc. - Pfizer Inc. - Procarta Biosystems Ltd - Prokarium Ltd. - Sanofi Pasteur SA - Sarum Biosciences Limited - Sequella, Inc. - Shire Plc - Sorrento Therapeutics, Inc. - Stellar Biotechnologies, Inc. - Summit Therapeutics plc. - Synthetic Biologics, Inc. For more information visit http://www.researchandmarkets.com/research/vg...lostridium
PFE: 34.78 (-0.10), SRNE: 24.31 (-0.05), INO: 7.23 (-0.09), SYN: 3.40 (-0.05), MRK: 58.07 (-0.06), SHPG: 261.24 (+1.78), ASMB: 17.39 (+0.25), OGEN: 1.89 (+0.19)
Low Back Pain Therapeutics Pipeline Review 2015 - 17 Companies & 19 Drug Profiles
M2 - Tue Jul 21, 10:23AM CDT
Research and Markets (http://www.researchandmarkets.com/research/qrggl2/low_back_pain) has announced the addition of the "Low Back Pain - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Low Back Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Low Back Pain and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Aestus Therapeutics, Inc. - Astellas Pharma Inc. - Collegium Pharmaceutical, Inc. - Eisai Co., Ltd. - Eli Lilly and Company - Frontier Biotechnologies Co., Ltd - Grunenthal GmbH - Ipsen S.A. - MEDRx Co., Ltd. - Merck & Co., Inc. - Mesoblast Limited - Nektar Therapeutics - Pacira Pharmaceuticals, Inc. - Paladin Labs Inc. - Pfizer Inc. - Stayble Therapeutics - Teikoku Pharma USA, Inc. Drug Profiles - (acetaminophen tramadol hydrochloride) - (diclofenac sodium eperisone) - (etodolac lidocaine) - (etoricoxib tizanidine) - (oxycodone hydrochloride naltrexone) ER - AB-001 - abobotulinumtoxin A - ASP-7962 - Atx09-002 - bupivacaine hydrochloride - cebranopadol - Drug for Chronic Low Back Pain - duloxetine hydrochloride DR - eperisone SR - flurbiprofen sodium - MPC-06ID - NKTR-181 - oxycodone hydrochloride ER - PF-06372865 For more information visit http://www.researchandmarkets.com/research/qr..._back_pain
PFE: 34.78 (-0.10), MRK: 58.07 (-0.06), COLL: 19.17 (-0.03), LLY: 86.76 (+0.38), PCRX: 62.10 (-0.03), NKTR: 12.72 (-0.07), PTIE: 1.72 (unch)
Epithelial Ovarian Cancer Pipeline Review 2015 - 49 Companies & 69 Drug Profiles
M2 - Tue Jul 21, 10:10AM CDT
Research and Markets (http://www.researchandmarkets.com/research/snr9r3/epithelial) has announced the addition of the "Epithelial Ovarian Cancer - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Epithelial Ovarian Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Epithelial Ovarian Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AbbVie Inc. - Adaptimmune Limited - Amgen Inc. - Astex Pharmaceuticals, Inc. - AstraZeneca PLC - Bayer AG - Bionomics Limited - BioNumerik Pharmaceuticals, Inc. - Boehringer Ingelheim GmbH - Celldex Therapeutics, Inc. - Celon Pharma Sp. z o.o. - Celsion Corporation - Cerulean Pharma, Inc. - Clovis Oncology, Inc. - Eli Lilly and Company - Exelixis, Inc. - F. Hoffmann-La Roche Ltd. - Genentech, Inc. - Glycotope GmbH - ImmunoGen, Inc. - Immunotope, Inc. - Johnson & Johnson - MabVax Therapeutics Holdings, Inc. - Merck & Co., Inc. - Millennium Pharmaceuticals, Inc. - NeoStem, Inc. - Novartis AG - Oasmia Pharmaceutical AB - OBI Pharma, Inc. - Oncobiologics, Inc. - Oncolytics Biotech Inc. - Onxeo SA - Otsuka Holdings Co., Ltd. - Pfizer Inc. - Pharma Mar, S.A. For more information visit http://www.researchandmarkets.com/research/snr9r3/epithelial
CLDX: 25.33 (-0.21), NBS: 2.25 (-0.09), CLSN: 2.50 (+0.09), JNJ: 100.20 (+0.02), ABBV: 70.52 (-0.04), EXEL: 5.88 (-0.43), ONCY: 0.61 (-0.03), CERU: 4.24 (+0.04), PFE: 34.78 (-0.10), IMGN: 18.15 (-0.77), AMGN: 164.10 (-0.15), LLY: 86.76 (+0.38), CLVS: 85.96 (-0.06), AZN: 66.55 (-0.67), MRK: 58.07 (-0.06), NVS: 103.05 (+1.75)
Diabetic Neuropathy Therapeutics Pipeline Review 2015 - 16 Companies & 28 Drug Profiles
M2 - Tue Jul 21, 10:06AM CDT
Research and Markets (http://www.researchandmarkets.com/research/phhqrf/diabetic) has announced the addition of the "Diabetic Neuropathy - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Diabetic Neuropathy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diabetic Neuropathy and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Acorda Therapeutics, Inc. - Araim Pharmaceuticals Inc. - Astellas Pharma Inc. - Cebix Incorporated - Eli Lilly and Company - Glucox Biotech AB - Longevity Biotech, Inc - Lpath, Inc. - Neuralstem, Inc. - Omeros Corporation - Pfizer Inc. - R-Tech Ueno, Ltd. - Spinifex Pharmaceuticals Pty Limited - Sumitomo Dainippon Pharma Co., Ltd. - Virobay Inc. - ViroMed Co., Ltd. Drug Profiles - Antimunocel - ARA-290 - ASP-8477 - BBI-21007 - Biologic for Diabetic Nephropathy - BNV-222 - capsaicin - CBX-129801 - Cyndacel-M - Drug for Peripheral Neuropathic Pain and Diabetic Peripheral Neuropathy - EMA-401 - ketoprofen - Lpathomab - Monoclonal Antibodies to Inhibit MASP-2 for Rheumatoid Arthritis and Diabetic Complications - NRD-135SE1 - NSI-566 - OMS-721 - Peptide to Activate G Protein-Coupled Receptor Mas for Cardiovascular, Metabolic Disorders and Erectile Dysfunction - PF-05089771 - ranirestat - Recombinant Protein to Antagonize VEGFR-2 for Oncology and Metabolic Disorders - RTU-1096 - Small Molecule to Inhibit NOX-4 for Diabetic Neuropathy - Small Molecules for Diabetic Neuropathy - Small Molecules for Peripheral Neuropathy and Amyotrophic Lateral Sclerosis - Synthetic Peptides for Central Nervous System Disorders and Diabetic Neuropathy - VBY-285 - VM-202 For more information visit http://www.researchandmarkets.com/research/phhqrf/diabetic
PFE: 34.78 (-0.10), LLY: 86.76 (+0.38), VBAY: (), ACOR: 34.75 (-0.48), LPTN: 0.32 (+0.06), OMER: 17.63 (-0.21), CUR: 1.93 (+0.25)
Cytomegalovirus (HHV-5) Infections Therapeutics Pipeline Review 2015 - 29 Companies & 62 Drug Profiles
M2 - Tue Jul 21, 10:04AM CDT
Research and Markets (http://www.researchandmarkets.com/research/48mmqt/cytomegalovirus) has announced the addition of the "Cytomegalovirus (HHV-5) Infections - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Cytomegalovirus (HHV-5) Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cytomegalovirus (HHV-5) Infections and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - 3-V Biosciences, Inc. - AIMM Therapeutics B.V. - AlphaVax, Inc. - Altor BioScience Corporation - Applied Immune Technologies Ltd - Astellas Pharma Inc. - BioApex, s.r.o. - Bionor Pharma ASA - Biotest AG - CAP-CMV GmbH - Cell Medica Limited - Chimerix, Inc. - GlaxoSmithKline plc - Hookipa Biotech AG - Humabs BioMed SA - INAGEN ApS - iQur Ltd. - Kadmon Corporation, LLC - Lead Discovery Center GmbH - Merck & Co., Inc. - Microbiotix, Inc. - Novartis AG - Pfizer Inc. - Phoenix Biotechnology, Inc. - Spider Biotech - Trellis Bioscience, Inc. - Vakzine Projekt Management GmbH - VBI Vaccines Inc. - Vical Incorporated For more information visit http://www.researchandmarkets.com/research/48...egalovirus
VICL: 0.63 (unch), CMRX: 52.35 (-0.59), PFE: 34.78 (-0.10), MRK: 58.07 (-0.06), VBIV: 2.47 (-0.03), GSK: 42.00 (-0.30), NVS: 103.05 (+1.75)
3 High-Dividend Pharmaceutical Stocks to Buy
at The Street - Tue Jul 21, 7:48AM CDT
With Eli Lilly & Co. experimenting with a new drug for Alzheimer's disease, we decided to check Quant Ratings for pharmaceutical stocks to buy.
JNJ: 100.20 (+0.02), PFE: 34.78 (-0.10), LLY: 86.76 (+0.38), NVS: 103.05 (+1.75)
Don't Sell Qualcomm; Stick With Companies That Have Growth
at The Street - Thu Jul 23, 2:04PM CDT
The CNBC 'Fast Money' traders debate whether now is a good time to sell Qualcomm, and discuss a raft of other stocks.
AMZN: 482.18 (-6.09), NKE: 114.00 (-0.09), FB: 95.44 (-1.60), PFE: 34.78 (-0.10), C: 59.87 (-0.47), LLY: 86.76 (+0.38), BMY: 68.24 (-1.13), INTC: 28.59 (-0.01), HPQ: 31.23 (+0.46), FINL: 27.44 (-0.43), NFLX: 110.10 (-1.40), UA: 95.93 (+6.56), JPM: 69.64 (-0.44), IBM: 161.73 (+1.38), QCOM: 61.78 (-2.41), FFIV: 127.68 (+9.18), CRUS: 35.72 (+5.01), GOOGL: 674.73 (-20.37), FL: 69.90 (-0.36), AAPL: 125.16 (-0.06), FTNT: 46.83 (+4.53), CSCO: 28.01 (+0.48)
Bristol-Myers Beats on Q2 Earnings, Raises 2015 Guidance - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 23, 12:32PM CDT
Bristol-Myers Squibb Company's (BMY) second-quarter 2015 earnings (excluding special items) of 53 cents per share beat the Zacks Consensus Estimate of 35 cents.
PFE: 34.78 (-0.10), SNSS: 3.47 (-0.05), AMAG: 71.31 (-1.23), BMY: 68.24 (-1.13)
How to Trade 5 Big Stocks for Big Gains -- Must-See Charts
at The Street - Thu Jul 23, 11:42AM CDT
Here's a technical look at how to trade some of the biggest stocks on Wall Street.
HD: 114.59 (-0.31), V: 71.75 (-0.22), GS: 211.05 (-2.20), CNI: 60.22 (-0.78), PFE: 34.78 (-0.10)
Zacks Industry Outlook Highlights: AbbVie, Allergan, Pfizer, Juno and Johnson & Johnson - Press Releases
Zacks Equity Research - Zacks Investment Research - Wed Jul 22, 8:30AM CDT
Zacks Industry Outlook Highlights: AbbVie, Allergan, Pfizer, Juno and Johnson & Johnson
AGN: 314.95 (-0.40), JNJ: 100.20 (+0.02), PFE: 34.78 (-0.10), JUNO: 51.65 (-0.12), ABBV: 70.52 (-0.04)
Pfizer Announces Expansion of Lease Agreement with Massachusetts Institute of Technology Subsidiary for Kendall Square Research Facility
Business Wire - Wed Jul 22, 7:30AM CDT
Pfizer announced today the expansion of its lease agreement with a subsidiary of Massachusetts Institute of Technology, creating a unified Pfizer campus in Kendall Square (KSQ). With this expansion, Pfizer has leased the full 500,000 square feet at 610 Main Street in Kendall Square. This space will continue to house the R&D activities that relocated to 610 Main Street in 2014, and will enable the consolidation of Pfizer's three other leased spaces in Cambridge into the one campus.
PFE: 34.78 (-0.10)
2015’s Top 6 Big Pharma Headlines Thus Far
George Budwell, The Motley Fool - Motley Fool - Wed Jul 22, 7:16AM CDT
The pharmaceutical industry has certainly gotten off to another wild start in 2015. Despite the year being only half over at this point, we've already seen dozens of high profile mergers, several closely-watched experimental drugs report pivotal...
JNJ: 100.20 (+0.02), PFE: 34.78 (-0.10), AMGN: 164.10 (-0.15), ABBV: 70.52 (-0.04), BMY: 68.24 (-1.13)
Bristol-Myers Shares Come With an Unhealthy Dose of Optimism
at The Street - Wed Jul 22, 5:15AM CDT
Bristol-Myers Squibb now trades at an unusually high price-to-earnings ratio of 51. If you own it, take some profits before Thursday's earnings report. If you don't, look elsewhere.
JNJ: 100.20 (+0.02), PFE: 34.78 (-0.10), BMY: 68.24 (-1.13)
Pfizer is expanding its vaccine portfolio, developing others
By The Associated Press - AP - Tue Jul 21, 5:08PM CDT
Pfizer has expanded its research on vaccines to eventually safeguard people from cradle to grave, from shots for pregnant women to protect their babies from the moment of birth to vaccines for senior citizens with waning immune systems, company officials said Tuesday during a media briefing.
BAX: 37.97 (+0.26), PFE: 34.78 (-0.10)
Business Highlights
By The Associated Press - AP - Tue Jul 21, 5:00PM CDT
___
JPM: 69.64 (-0.44), PFE: 34.78 (-0.10), C: 59.87 (-0.47), AMGN: 164.10 (-0.15), BAC: 18.18 (-0.27)
Pharma Stock Outlook - July 2015 - Zacks Analyst Interviews
Arpita Dutt - Zacks Investment Research - Tue Jul 21, 1:52PM CDT
Pharma Stock Outlook - July 2015 - Zacks Analyst Interviews
AGN: 314.95 (-0.40), JNJ: 100.20 (+0.02), ACHN: 8.97 (-0.12), PFE: 34.78 (-0.10), ABBV: 70.52 (-0.04), JUNO: 51.65 (-0.12), LLY: 86.76 (+0.38), SNY: 53.37 (+0.28)
Pharma Stock Outlook - July 2015 - Industry Outlook
Arpita Dutt - Zacks Investment Research - Tue Jul 21, 1:52PM CDT
Pharma Stock Outlook - July 2015 - Industry Outlook
AGN: 314.95 (-0.40), JNJ: 100.20 (+0.02), ACHN: 8.97 (-0.12), PFE: 34.78 (-0.10), ABBV: 70.52 (-0.04), JUNO: 51.65 (-0.12), LLY: 86.76 (+0.38), SNY: 53.37 (+0.28)
Europe approves Amgen's first-in-class cholesterol drug
By MATTHEW PERRONE - AP - Tue Jul 21, 1:32PM CDT
WASHINGTON (AP) — Amgen on Tuesday received European approval for its first-of-a-kind cholesterol drug that lowers levels of the artery-clogging substance more than older drugs that have been prescribed for decades.
PFE: 34.78 (-0.10), AMGN: 164.10 (-0.15)
Global Fibrosis Therapeutics Pipeline Report 2015 - 32 Companies & 51 Drug Profiles
M2 - Tue Jul 21, 10:39AM CDT
Research and Markets (http://www.researchandmarkets.com/research/rjw3lt/fibrosis) has announced the addition of the "Fibrosis - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Fibrosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Fibrosis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Acceleron Pharma, Inc. - AiCuris GmbH & Co. KG - AnaMar AB - Arena Pharmaceuticals, Inc. - Bristol-Myers Squibb Company - Digna Biotech, S.L. - F. Hoffmann-La Roche Ltd. - FibroGen, Inc. - Five Prime Therapeutics, Inc. - Galectin Therapeutics, Inc. - GenKyoTex S.A. - GlycoMimetics, Inc. - HanAll Biopharma Co., Ltd. - Intercept Pharmaceuticals, Inc. - Isarna Therapeutics GmbH - KineMed, Inc. - Lycera Corp. - MandalMed, Inc. - miRagen Therapeutics, Inc. - Neumedicines Inc. - Pfizer Inc. - Promedior, Inc. - ProMetic Life Sciences Inc. - RuiYi Inc. - Scholar Rock, Inc. - Siena Biotech S.p.A. - SK Chemicals Co., Ltd. - Taisho Pharmaceutical Co., Ltd. - TRACON Pharmaceuticals, Inc. - UCB S.A. - Vericel Corporation - VivaCell Biotechnology Espana S.L. For more information visit http://www.researchandmarkets.com/research/rjw3lt/fibrosis
VCEL: 3.47 (-0.03), KNMD: (), PFE: 34.78 (-0.10), GALT: 2.83 (+0.10), GLYC: 7.52 (+0.05), BMY: 68.24 (-1.13), ICPT: 280.00 (+10.69), FGEN: 24.71 (+0.25), TCON: 13.02 (-0.14), ARNA: 4.15 (-0.10), XLRN: 31.50 (-0.68), FPRX: 24.47 (-0.58)
Sickle Cell Disease Pipeline Review, H1 2015 - 27 Companies & 48 Drug Profiles
M2 - Tue Jul 21, 10:39AM CDT
Research and Markets (http://www.researchandmarkets.com/research/rrc4sf/sickle_cell) has announced the addition of the "Sickle Cell Disease - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Sickle Cell Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Sickle Cell Disease and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Acceleron Pharma, Inc. - Acetylon Pharmaceuticals, Inc. - Addex Therapeutics Ltd - Advinus Therapeutics Ltd. - Alnylam Pharmaceuticals, Inc. - Bluebird bio, Inc. - Bristol-Myers Squibb Company - Daiichi Sankyo Company, Limited - Dilaforette AB - Emmaus Medical, Inc. - Errant Gene Therapeutics, LLC - Erytech Pharma SA - Gamida Cell Ltd. - Gilead Sciences, Inc. - Global Blood Therapeutics, Inc. - Isis Pharmaceuticals, Inc. - Johnson & Johnson - Morphogenesis, Inc. - NKT Therapeutics, Inc. - Novartis AG - Pfizer Inc. - PharmaEssentia Corporation - Prolong Pharmaceuticals - ReveraGen BioPharma, Inc. - Sangamo BioSciences, Inc. - Sanofi - SynZyme Technologies, LLC For more information visit http://www.researchandmarkets.com/research/rr...ickle_cell
JNJ: 100.20 (+0.02), ISIS: 55.08 (-0.30), GILD: 117.66 (+0.22), PFE: 34.78 (-0.10), SGMO: 8.83 (-0.77), BMY: 68.24 (-1.13), NVS: 103.05 (+1.75), XLRN: 31.50 (-0.68)
Clostridium Difficile Infections (Clostridium Difficile Associated Disease) Therapeutics Pipeline Report 2015 - 37 Companies & 57 Drug Profiles
M2 - Tue Jul 21, 10:33AM CDT
Research and Markets (http://www.researchandmarkets.com/research/vgmkjs/clostridium) has announced the addition of the "Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Clostridium Difficile Infections (Clostridium Difficile Associated Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Clostridium Difficile Infections (Clostridium Difficile Associated Disease) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Absynth Biologics Limited - Actelion Ltd - ActogeniX NV - Adenium Biotech ApS - AIMM Therapeutics B.V. - Akthelia pharmaceuticals ehf - AmpliPhi Biosciences Corporation - Assembly Biosciences, Inc. - AvidBiotics Corp. - C3 Jian, Inc - Daiichi Sankyo Company, Limited - Evec, Inc. - GangaGen Inc. - ImmunoBiology Ltd. - Immuron Limited - Inovio Pharmaceuticals, Inc. - MedImmune, LLC - Merck & Co., Inc. - MGB Biopharma Limited - Microbiotix, Inc. - Micropharm Ltd - Nanotherapeutics, Inc. - Novabiotics Ltd - Oragenics, Inc. - Pfizer Inc. - Procarta Biosystems Ltd - Prokarium Ltd. - Sanofi Pasteur SA - Sarum Biosciences Limited - Sequella, Inc. - Shire Plc - Sorrento Therapeutics, Inc. - Stellar Biotechnologies, Inc. - Summit Therapeutics plc. - Synthetic Biologics, Inc. For more information visit http://www.researchandmarkets.com/research/vg...lostridium
PFE: 34.78 (-0.10), SRNE: 24.31 (-0.05), INO: 7.23 (-0.09), SYN: 3.40 (-0.05), MRK: 58.07 (-0.06), SHPG: 261.24 (+1.78), ASMB: 17.39 (+0.25), OGEN: 1.89 (+0.19)
Low Back Pain Therapeutics Pipeline Review 2015 - 17 Companies & 19 Drug Profiles
M2 - Tue Jul 21, 10:23AM CDT
Research and Markets (http://www.researchandmarkets.com/research/qrggl2/low_back_pain) has announced the addition of the "Low Back Pain - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Low Back Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Low Back Pain and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Aestus Therapeutics, Inc. - Astellas Pharma Inc. - Collegium Pharmaceutical, Inc. - Eisai Co., Ltd. - Eli Lilly and Company - Frontier Biotechnologies Co., Ltd - Grunenthal GmbH - Ipsen S.A. - MEDRx Co., Ltd. - Merck & Co., Inc. - Mesoblast Limited - Nektar Therapeutics - Pacira Pharmaceuticals, Inc. - Paladin Labs Inc. - Pfizer Inc. - Stayble Therapeutics - Teikoku Pharma USA, Inc. Drug Profiles - (acetaminophen tramadol hydrochloride) - (diclofenac sodium eperisone) - (etodolac lidocaine) - (etoricoxib tizanidine) - (oxycodone hydrochloride naltrexone) ER - AB-001 - abobotulinumtoxin A - ASP-7962 - Atx09-002 - bupivacaine hydrochloride - cebranopadol - Drug for Chronic Low Back Pain - duloxetine hydrochloride DR - eperisone SR - flurbiprofen sodium - MPC-06ID - NKTR-181 - oxycodone hydrochloride ER - PF-06372865 For more information visit http://www.researchandmarkets.com/research/qr..._back_pain
PFE: 34.78 (-0.10), MRK: 58.07 (-0.06), COLL: 19.17 (-0.03), LLY: 86.76 (+0.38), PCRX: 62.10 (-0.03), NKTR: 12.72 (-0.07), PTIE: 1.72 (unch)
Epithelial Ovarian Cancer Pipeline Review 2015 - 49 Companies & 69 Drug Profiles
M2 - Tue Jul 21, 10:10AM CDT
Research and Markets (http://www.researchandmarkets.com/research/snr9r3/epithelial) has announced the addition of the "Epithelial Ovarian Cancer - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Epithelial Ovarian Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Epithelial Ovarian Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AbbVie Inc. - Adaptimmune Limited - Amgen Inc. - Astex Pharmaceuticals, Inc. - AstraZeneca PLC - Bayer AG - Bionomics Limited - BioNumerik Pharmaceuticals, Inc. - Boehringer Ingelheim GmbH - Celldex Therapeutics, Inc. - Celon Pharma Sp. z o.o. - Celsion Corporation - Cerulean Pharma, Inc. - Clovis Oncology, Inc. - Eli Lilly and Company - Exelixis, Inc. - F. Hoffmann-La Roche Ltd. - Genentech, Inc. - Glycotope GmbH - ImmunoGen, Inc. - Immunotope, Inc. - Johnson & Johnson - MabVax Therapeutics Holdings, Inc. - Merck & Co., Inc. - Millennium Pharmaceuticals, Inc. - NeoStem, Inc. - Novartis AG - Oasmia Pharmaceutical AB - OBI Pharma, Inc. - Oncobiologics, Inc. - Oncolytics Biotech Inc. - Onxeo SA - Otsuka Holdings Co., Ltd. - Pfizer Inc. - Pharma Mar, S.A. For more information visit http://www.researchandmarkets.com/research/snr9r3/epithelial
CLDX: 25.33 (-0.21), NBS: 2.25 (-0.09), CLSN: 2.50 (+0.09), JNJ: 100.20 (+0.02), ABBV: 70.52 (-0.04), EXEL: 5.88 (-0.43), ONCY: 0.61 (-0.03), CERU: 4.24 (+0.04), PFE: 34.78 (-0.10), IMGN: 18.15 (-0.77), AMGN: 164.10 (-0.15), LLY: 86.76 (+0.38), CLVS: 85.96 (-0.06), AZN: 66.55 (-0.67), MRK: 58.07 (-0.06), NVS: 103.05 (+1.75)
Diabetic Neuropathy Therapeutics Pipeline Review 2015 - 16 Companies & 28 Drug Profiles
M2 - Tue Jul 21, 10:06AM CDT
Research and Markets (http://www.researchandmarkets.com/research/phhqrf/diabetic) has announced the addition of the "Diabetic Neuropathy - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Diabetic Neuropathy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diabetic Neuropathy and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Acorda Therapeutics, Inc. - Araim Pharmaceuticals Inc. - Astellas Pharma Inc. - Cebix Incorporated - Eli Lilly and Company - Glucox Biotech AB - Longevity Biotech, Inc - Lpath, Inc. - Neuralstem, Inc. - Omeros Corporation - Pfizer Inc. - R-Tech Ueno, Ltd. - Spinifex Pharmaceuticals Pty Limited - Sumitomo Dainippon Pharma Co., Ltd. - Virobay Inc. - ViroMed Co., Ltd. Drug Profiles - Antimunocel - ARA-290 - ASP-8477 - BBI-21007 - Biologic for Diabetic Nephropathy - BNV-222 - capsaicin - CBX-129801 - Cyndacel-M - Drug for Peripheral Neuropathic Pain and Diabetic Peripheral Neuropathy - EMA-401 - ketoprofen - Lpathomab - Monoclonal Antibodies to Inhibit MASP-2 for Rheumatoid Arthritis and Diabetic Complications - NRD-135SE1 - NSI-566 - OMS-721 - Peptide to Activate G Protein-Coupled Receptor Mas for Cardiovascular, Metabolic Disorders and Erectile Dysfunction - PF-05089771 - ranirestat - Recombinant Protein to Antagonize VEGFR-2 for Oncology and Metabolic Disorders - RTU-1096 - Small Molecule to Inhibit NOX-4 for Diabetic Neuropathy - Small Molecules for Diabetic Neuropathy - Small Molecules for Peripheral Neuropathy and Amyotrophic Lateral Sclerosis - Synthetic Peptides for Central Nervous System Disorders and Diabetic Neuropathy - VBY-285 - VM-202 For more information visit http://www.researchandmarkets.com/research/phhqrf/diabetic
PFE: 34.78 (-0.10), LLY: 86.76 (+0.38), VBAY: (), ACOR: 34.75 (-0.48), LPTN: 0.32 (+0.06), OMER: 17.63 (-0.21), CUR: 1.93 (+0.25)
Cytomegalovirus (HHV-5) Infections Therapeutics Pipeline Review 2015 - 29 Companies & 62 Drug Profiles
M2 - Tue Jul 21, 10:04AM CDT
Research and Markets (http://www.researchandmarkets.com/research/48mmqt/cytomegalovirus) has announced the addition of the "Cytomegalovirus (HHV-5) Infections - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Cytomegalovirus (HHV-5) Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cytomegalovirus (HHV-5) Infections and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - 3-V Biosciences, Inc. - AIMM Therapeutics B.V. - AlphaVax, Inc. - Altor BioScience Corporation - Applied Immune Technologies Ltd - Astellas Pharma Inc. - BioApex, s.r.o. - Bionor Pharma ASA - Biotest AG - CAP-CMV GmbH - Cell Medica Limited - Chimerix, Inc. - GlaxoSmithKline plc - Hookipa Biotech AG - Humabs BioMed SA - INAGEN ApS - iQur Ltd. - Kadmon Corporation, LLC - Lead Discovery Center GmbH - Merck & Co., Inc. - Microbiotix, Inc. - Novartis AG - Pfizer Inc. - Phoenix Biotechnology, Inc. - Spider Biotech - Trellis Bioscience, Inc. - Vakzine Projekt Management GmbH - VBI Vaccines Inc. - Vical Incorporated For more information visit http://www.researchandmarkets.com/research/48...egalovirus
VICL: 0.63 (unch), CMRX: 52.35 (-0.59), PFE: 34.78 (-0.10), MRK: 58.07 (-0.06), VBIV: 2.47 (-0.03), GSK: 42.00 (-0.30), NVS: 103.05 (+1.75)
3 High-Dividend Pharmaceutical Stocks to Buy
at The Street - Tue Jul 21, 7:48AM CDT
With Eli Lilly & Co. experimenting with a new drug for Alzheimer's disease, we decided to check Quant Ratings for pharmaceutical stocks to buy.
JNJ: 100.20 (+0.02), PFE: 34.78 (-0.10), LLY: 86.76 (+0.38), NVS: 103.05 (+1.75)
